Dmitry O. Koltun is currently a Senior Scientist II in the Department of Medicinal Chemistry, Gilead Sciences (Foster City, CA), which he joined in 2009. While at Gilead, he developed interest in Immuno-Oncology, Cardiovascular, and CNS research, and co-invented a number of Development Candidates. His most advanced Candidate reached Phase III Clinical Trials for a number of Cardiovascular indications, and 2 more molecules are in IND Toxicology studies (one is being developed internally for Immuno-Oncology and one is partnered with an outside company for CNS indications). Prior to Gilead, Dmitry worked at CV Therapeutics (Palo Alto, CA) from 2002 to 2009 and conducted research in Cardiovascular and Metabolic diseases. Dmitry obtained his Ph.D. in 1999 at the University of Minnesota under the mentorship of Prof. Thomas Hoye and an M.S. degree in 1994 in Moscow at the Higher Chemical College of the Russian Academy of Sciences. He is an author of over 60 papers and patent applications.